 |
27 Products |  |
63 Diseases | | 27 Products |
|
80 Trials |  |
3278 News |  |
| «12...37383940414243444546474849» |
- | Innohep (tinzaparin) / LEO Pharma
New P4 trial: Use of Tinzaparin for Anticoagulation in Hemodialysis (clinicaltrials.gov) - Aug 26, 2013
P4, N=180, Not yet recruiting, Sponsor: Christine Ribic
- ||||| ingenol disoxate (LEO 43204) / LEO Pharma
New P1/2 trial: A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis (clinicaltrials.gov) - Aug 12, 2013
P1/2, N=588, Recruiting, Sponsor: LEO Pharma
- ||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Enrollment closed: A Phase 3 Clinical Study of KHK4827 (clinicaltrials.gov) - Jul 25, 2013
P3, N=140, Active, not recruiting, Sponsor: Kyowa Hakko Kirin Company, Limited
Enrolling by invitation --> Active, not recruiting
- ||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
New P2 trial: Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility (clinicaltrials.gov) - Jul 16, 2013
P2, N=566, Recruiting, Sponsor: Amgen
- |||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Enrollment open: Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility (clinicaltrials.gov) - Jul 15, 2013
P2, N=566, Recruiting, Sponsor: Amgen
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- | SPS4251 / Circassia
Trial completion: Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris (clinicaltrials.gov) - Jul 15, 2013
P1, N=24, Completed, Sponsor: Circassia Limited
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
Enrollment change: Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris (clinicaltrials.gov) - Jul 8, 2013
P2, N=37, Completed, Sponsor: LEO Pharma
Recruiting --> Completed N=30 --> 37
- | Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
Trial completion: Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris (clinicaltrials.gov) - Jul 8, 2013
P2, N=37, Completed, Sponsor: LEO Pharma
N=30 --> 37 Recruiting --> Completed
- |||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Trial completion: Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis (clinicaltrials.gov) - Jul 8, 2013
P2a, N=111, Completed, Sponsor: AstraZeneca
Recruiting --> Completed Active, not recruiting --> Completed
- Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Enrollment closed: An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis (clinicaltrials.gov) - Jun 9, 2013
P3, N=0, Active, not recruiting, Sponsor: Kyowa Hakko Kirin Company, Limited
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Trial completion: A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma (clinicaltrials.gov) - May 30, 2013
P2, N=315, Completed, Sponsor: Amgen
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
New P3 trial: LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris (clinicaltrials.gov) - May 29, 2013
P3, N=426, Completed, Sponsor: LEO Pharma
- Innohep (tinzaparin) / LEO Pharma
Enrollment change: Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer (clinicaltrials.gov) - May 22, 2013
P2, N=131, Terminated, Sponsor: University of Southern California
Active, not recruiting --> Completed N=200 --> 131
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
Trial completion: A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma (clinicaltrials.gov) - May 21, 2013
P1, N=22, Completed, Sponsor: MedImmune LLC
N=200 --> 131 Active, not recruiting --> Completed
- LEO 29102 / LEO Pharma
Trial termination: Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. (clinicaltrials.gov) - Apr 29, 2013
P1, N=58, Terminated, Sponsor: LEO Pharma
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- LEO 29102 / LEO Pharma
Enrollment change: Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. (clinicaltrials.gov) - Apr 29, 2013
P1, N=58, Terminated, Sponsor: LEO Pharma
Active, not recruiting --> Terminated N=74 --> 58
- calcipotriol/betamethasone dipropionate / Generic mfg.
Enrollment closed: PSTaclonex: Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris (clinicaltrials.gov) - Apr 14, 2013
P=N/A, N=20, Active, not recruiting, Sponsor: Wake Forest University
N=74 --> 58 Recruiting --> Active, not recruiting
- | Fragmin (dalteparin sodium) / Pfizer, Eisai, Fraxiparine (nadroparin) / Aspen, Innohep (tinzaparin) / LEO Pharma
New P4 trial: Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy (clinicaltrials.gov) - Apr 9, 2013
P4, N=1000, Recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- ||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Enrollment closed: AMAGINE-1: Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (clinicaltrials.gov) - Mar 31, 2013
P3, N=661, Active, not recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Fragmin (dalteparin sodium) / Pfizer, Eisai, Innohep (tinzaparin) / LEO Pharma
New P2 trial, HEOR, Cost effectiveness: ALICAT: Anticoagulation Length in Cancer Associated Thrombosis (clinicaltrials.gov) - Mar 21, 2013
P2, N=200, Not yet recruiting, Sponsor: Cardiff University
- |||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
Trial completion: LEO 90100 in the Treatment of Psoriasis Vulgaris (clinicaltrials.gov) - Mar 5, 2013
P2, N=303, Completed, Sponsor: LEO Pharma
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
Trial completion: LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (clinicaltrials.gov) - Mar 5, 2013
P2, N=376, Completed, Sponsor: LEO Pharma
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Enrollment closed: AMG 827 in Subjects With Psoriatic Arthritis (clinicaltrials.gov) - Feb 20, 2013
P2, N=168, Active, not recruiting, Sponsor: Amgen
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Desonate (desonide gel) / LEO Pharma
Trial completion: Efficacy Emollient on Xerosis in Children With Atopic Dermatitis (clinicaltrials.gov) - Feb 19, 2013
P3, N=251, Completed, Sponsor: Pierre Fabre Medicament
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Dovonex (calcipotriol) / LEO Pharma, Novartis
Enrollment closed: SHP-141C in Plaque Type Psoriasis (clinicaltrials.gov) - Feb 5, 2013
P1, N=14, Active, not recruiting, Sponsor: Shape Pharmaceuticals Pty Ltd.
Active, not recruiting --> Completed Not yet recruiting --> Active, not recruiting
- | Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
New P3 trial: An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis (clinicaltrials.gov) - Jan 31, 2013
P3, N=0, Active, not recruiting, Sponsor: Kyowa Hakko Kirin Company, Limited
- |||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
New P3 trial: A Phase 3 Clinical Study of KHK4827 (clinicaltrials.gov) - Jan 31, 2013
P3, N=140, Active, not recruiting, Sponsor: Kyowa Hakko Kirin Company, Limited
- Innohep (tinzaparin) / LEO Pharma
Trial suspension: Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis (clinicaltrials.gov) - Jan 25, 2013
P4, N=200, Suspended, Sponsor: Anemia Working Group Romania
Not yet recruiting --> Active, not recruiting Not yet recruiting --> Suspended
- Innohep (tinzaparin) / LEO Pharma
Trial initiation date: Effects of Tinzaparin on Cardio-vascular Outcomes and on Blood Lipids in Diabetic Patients on Chronic Hemodialysis (clinicaltrials.gov) - Jan 25, 2013
P4, N=200, Suspended, Sponsor: Anemia Working Group Romania
Not yet recruiting --> Suspended Initiation date: Mar 2008 --> Mar 2009
- || LEO 29102 / LEO Pharma
Enrollment change: Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102 (clinicaltrials.gov) - Jan 24, 2013
P1, N=102, Completed, Sponsor: LEO Pharma
Initiation date: Mar 2008 --> Mar 2009 N=72 --> 102
- ||| LEO 29102 / LEO Pharma
Trial completion: Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102 (clinicaltrials.gov) - Jan 24, 2013
P1, N=102, Completed, Sponsor: LEO Pharma
N=72 --> 102 Recruiting --> Completed
- | Dovonex (calcipotriol) / LEO Pharma, Novartis
Trial initiation date: "Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy" (clinicaltrials.gov) - Jan 23, 2013
P2/3, N=54, Active, not recruiting, Sponsor: University of California, Los Angeles
Recruiting --> Completed Initiation date: Oct 2012 --> Feb 2013
- | Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Trial termination: Safety and Efficacy of AMG 827 in Subjects With RA (clinicaltrials.gov) - Jan 21, 2013
P2, N=211, Terminated, Sponsor: Amgen
Initiation date: Oct 2012 --> Feb 2013 Not yet recruiting --> Terminated; Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA)
- || orismilast oral (LEO 32731) / UNION Therap
Enrollment change: LEO 32731 - A Study in Healthy Male Subjects (clinicaltrials.gov) - Jan 10, 2013
P1, N=111, Completed, Sponsor: LEO Pharma
Not yet recruiting --> Terminated; Lack of efficacy for Brodalumab in Rheumatoid Arthritis (RA) N=80 --> 111
- ||| orismilast oral (LEO 32731) / UNION Therap
Trial completion: LEO 32731 - A Study in Healthy Male Subjects (clinicaltrials.gov) - Jan 10, 2013
P1, N=111, Completed, Sponsor: LEO Pharma
N=80 --> 111 Recruiting --> Completed
- ||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
New P2 trial: A Phase 2 Clinical Study of KHK4827 (clinicaltrials.gov) - Dec 10, 2012
P2, N=140, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
- | SPS4251 / Circassia
New P1 trial: Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris (clinicaltrials.gov) - Dec 4, 2012
P1, N=24, Completed, Sponsor: Circassia Limited
- Desonate (desonide gel) / LEO Pharma
Trial completion: Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation (clinicaltrials.gov) - Nov 26, 2012
P4, N=28, Completed, Sponsor: Universidad Autonoma de San Luis PotosÃ
Recruiting --> Completed Active, not recruiting --> Completed
- | Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
Trial completion: A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis (clinicaltrials.gov) - Oct 31, 2012
P1, N=48, Completed, Sponsor: Kyowa Hakko Kirin Company, Limited
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Kirin
New P3 trial: AMAGINE-1: Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis Subjects (clinicaltrials.gov) - Oct 15, 2012
P3, N=661, Active, not recruiting, Sponsor: Amgen
- |||||||||| Siliq (brodalumab) / Bausch Health
New P3 trial: AMAGINE-3: Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (clinicaltrials.gov) - Oct 15, 2012
P3, N=1881, Active, not recruiting, Sponsor: Amgen
- |||||||||| Siliq (brodalumab) / Bausch Health
New P3 trial: AMAGINE-2: P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Oct 15, 2012
P3, N=1800, Active, not recruiting, Sponsor: Amgen
- |||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
Enrollment open, P2 data: A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - Oct 10, 2012
P2, N=302, Recruiting, Sponsor: MedImmune LLC
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Dovonex (calcipotriol) / LEO Pharma, Novartis
New P2/3 trial: "Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy" (clinicaltrials.gov) - Sep 25, 2012
P2/3, N=54, Active, not recruiting, Sponsor: University of California, Los Angeles
- | Dovonex (calcipotriol) / LEO Pharma, Novartis
New P1 trial: SHP-141C in Plaque Type Psoriasis (clinicaltrials.gov) - Jul 18, 2012
P1, N=14, Active, not recruiting, Sponsor: Shape Pharmaceuticals Pty Ltd.
- | LEO 35299 / LEO Pharma
Trial completion: A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris (clinicaltrials.gov) - Jul 8, 2012
P1, N=24, Completed, Sponsor: LEO Pharma
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||||| Adbry (tralokinumab) / LEO Pharma, AstraZeneca
New P2 trial, P2 data: A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - Jun 25, 2012
P2, N=302, Recruiting, Sponsor: MedImmune LLC
- | Enstilar (calcipotriene/betamethasone dipropionate) / LEO Pharma
New P2 trial: Effect of LEO 90100 on the HPA Axis and Calcium Metabolism in Subjects With Extensive Psoriasis VulgarisExtensive Psoriasis Vulgaris (clinicaltrials.gov) - May 15, 2012
P2, N=37, Completed, Sponsor: LEO Pharma
- | Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
New P1 trial: A Phase 1, Open-label Study to Investigate the Pharmacokinetics of Tralokinumab (CAT-354) in Adolescents With Asthma (clinicaltrials.gov) - May 3, 2012
P1, N=22, Completed, Sponsor: MedImmune LLC
- ||||||| Dovonex (calcipotriol) / LEO Pharma, Novartis
Trial completion: LEO 90105 Ointment in Japanese Subjects With Psoriasis (clinicaltrials.gov) - Apr 29, 2012
P3, N=677, Completed, Sponsor: LEO Pharma
Recruiting --> Completed Recruiting --> Completed